Corvus Doubles Down on China with $13.5M Investment in Angel Pharma
Event summary
- Corvus Pharmaceuticals invested $5M in a $13.5M financing round for Angel Pharmaceuticals, its China-based partner.
- Funding will support Phase 1b/2 trial for atopic dermatitis and a new Phase 2 asthma trial for soquelitinib in China.
- Corvus anticipates initial trial results for atopic dermatitis in late 2026 and Phase 2 asthma trial initiation in early 2027.
- Corvus holds a 49% equity stake in Angel Pharmaceuticals, maintaining significant influence over strategic decisions.
The big picture
Corvus' additional investment in Angel Pharmaceuticals underscores its strategic focus on expanding into China's growing immunology market. The move comes as biotech firms increasingly look to China for clinical development and commercialization opportunities, driven by its large patient population and regulatory streamlining. Corvus' 49% stake in Angel Pharmaceuticals positions it to benefit from both clinical milestones and potential commercial success of soquelitinib in key indications like atopic dermatitis and asthma.
What we're watching
- Clinical Progress
- Whether Angel Pharmaceuticals can deliver positive Phase 1b/2 results for soquelitinib in atopic dermatitis by late 2026.
- Market Expansion
- How Corvus leverages its 49% stake in Angel Pharmaceuticals to capture the large Chinese inflammation and immunology markets.
- Regulatory Dynamics
- The impact of U.S.-China relations on Corvus' ability to commercialize soquelitinib in China.